SCHEMBL8773474

SCHEMBL8773474

CC(C)(C)OC(=O)NC1CCN(C(=O)c2ccc(-n3ncc4cc(NC(=O)c5ccc(N6CCC(O)CC6)cc5)ccc43)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.47
BTK Q06187 1/20 0.42
MAOB P27338 1/20 0.41
MAPT P10636 4/20 0.39
TP53 P04637 2/20 0.39
THRB P10828 2/20 0.39
ATM Q13315 1/20 0.39
SUV39H2 Q9H5I1 1/20 0.38
MERTK Q12866 1/20 0.38
HPGDS O60760 1/20 0.38
MGLL Q99685 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
POLB P06746 1/20 0.38
SMO Q99835 1/20 0.38
NPC1L1 Q9UHC9 1/20 0.38
LMNA P02545 1/20 0.38
MAPK8 P45983 2/20 0.37
MAPK10 P53779 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8773439 0.90 MAPT (0.47) MAPTTP53THRBPOLBLMNA
SCHEMBL1665270 0.89 MGLL (0.43) NAMPTMAOBMAPTHPGDSMGLL
SCHEMBL8771617 0.88 MGLL (0.46) NAMPTMAOBMAPTMGLLPOLB
SCHEMBL27918319 0.85 MAOB (0.41) MAOBMAPTTP53THRBMGLL
SCHEMBL1665009 0.84 TNIK (0.44) NAMPTMAOBMAPTMGLLPOLB
SCHEMBL1664251 0.84 MAOB (0.45) NAMPTMAOBMAPTHPGDSPOLB
SCHEMBL1664266 0.83 MAPT (0.46) MAOBMAPTTP53ATMHPGDS
SCHEMBL1664924 0.83 MAOB (0.46) MAOBMAPTHPGDSMAPK8MAPK10
SCHEMBL6126223 0.83 MAOB (0.42) MAOBMAPTTP53MGLLPOLB
SCHEMBL1664478 0.81 MAOB (0.46) NAMPTMAOBMAPTHPGDSPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
CN-103282034-A Use of hematopoietic growth factor mimetics LIGAND PHARM INC 2013-09-04 CN disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL NAMPT 2248/4885BTK 2453/4885MAOB 4300/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF NAMPT 3076/4885BTK 213/4885MAOB 4439/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF NAMPT 3076/4885BTK 213/4885MAOB 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.